Conigen Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $2.5M

Overview

Conigen Bioscience is a private, early-revenue stage company founded in 2017, specializing in advanced recombinant protein and antibody discovery tools for biomedical research. Leveraging its proprietary CSP™ (soluble proteins) and CMP™ (membrane-associated virus-like particles) platforms, Conigen produces natively folded, multimeric proteins that serve as superior immunogens and assay reagents for challenging target classes such as GPCRs, ion channels, and immune checkpoint receptors. The company operates primarily as a platform and services business, catering to pharmaceutical and biotech partners in oncology and other therapeutic areas, with leadership from experienced entrepreneurs like CEO Jean Qiu, PhD. While not a therapeutic developer itself, Conigen's tools are intended to accelerate and de-risk the early-stage drug discovery pipeline for its clients.

Oncology

Technology Platform

Proprietary CSP™ (Conigen Soluble Proteins) and CMP™ (Conigen Membrane Proteins) platforms for engineering recombinant proteins that preserve native multimeric conformation and membrane-associated structure. CSP produces soluble ectodomain dimers of single-pass receptors. CMP presents full-length multi-pass proteins (GPCRs, ion channels) in virus-like particles (VLPs) to maintain native folding in a lipid bilayer.

Funding History

1

Total raised:$2.5M

Seed$2.5MUndisclosedJun 15, 2019

Opportunities

The growing demand for antibodies against complex membrane protein targets (GPCRs, ion channels) in drug discovery presents a major opportunity.

Conigen's platforms are specifically designed to overcome the immunogen challenge for these targets, positioning it as a critical enabler for next-generation biotherapeutics.

Expansion of catalog products and securing strategic partnerships with large biopharma companies could drive significant revenue growth.

Risk Factors

Intense competition from large, established reagent suppliers and CROs poses a market penetration risk.

The company's project-based revenue model may lead to volatility and requires continuous business development success.

There is also technology adoption risk, as researchers may be reluctant to switch from traditional, albeit less optimal, protein reagents and immunization methods.

Competitive Landscape

Conigen competes in the life science tools and antibody discovery services market against giants like Thermo Fisher Scientific and Abcam, as well as specialized recombinant protein vendors (e.g., Sino Biological, ACROBiosystems) and antibody discovery CROs. Its key differentiation is the claimed superior conformational fidelity of its proteins, specifically for multi-pass membrane targets, a niche where few competitors have robust solutions.

More companies in Proteomics & Protein Engineering →More companies in United States →